[1] V. J. Thannickal, G. B. Toews, E. S. White, J. P. Lynch, and F. J. Martinez, “Mechanisms of Pulmonary Fibrosis,” https://doi.org/10.1146/annurev.med.55.091902.103810, vol. 55, pp. 395–417, Jan. 2004, doi: 10.1146/ANNUREV.MED.55.091902.103810.
[2] P. M. George et al., “Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities,” The Lancet. Respiratory medicine, vol. 8, no. 9, pp. 925–934, Sep. 2020, doi: 10.1016/S2213-2600(20)30355-6.
[3] S. R. Ambardar, S. L. Hightower, N. A. Huprikar, K. K. Chung, A. Singhal, and J. F. Collen, “Post-COVID-19 Pulmonary Fibrosis: Novel Sequelae of the Current Pandemic,” Journal of clinical medicine, vol. 10, no. 11, Jun. 2021, doi: 10.3390/JCM10112452.
[4] X. Liu, H. Liu, X. Jia, R. He, X. Zhang, and W. Zhang, “Changing Expression Profiles of Messenger RNA, MicroRNA, Long Non-coding RNA, and Circular RNA Reveal the Key Regulators and Interaction Networks of Competing Endogenous RNA in Pulmonary Fibrosis,” Frontiers in Genetics, vol. 11, p. 1098, Sep. 2020, doi: 10.3389/FGENE.2020.558095/BIBTEX.
[5] K. M. Antoniou, A. Pataka, D. Bouros, and N. M. Siafakas, “Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis,” Pulmonary Pharmacology and Therapeutics, vol. 20, no. 5, pp. 453–461, Oct. 2007, doi: 10.1016/J.PUPT.2006.01.002.
[6] J. S. Mattick and I. v. Makunin, “Non-coding RNA,” Human Molecular Genetics, vol. 15, no. suppl_1, pp. R17–R29, Apr. 2006, doi: 10.1093/HMG/DDL046.
[7] M. Esteller, “Non-coding RNAs in human disease,” Nature Reviews Genetics 2011 12:12, vol. 12, no. 12, pp. 861–874, Nov. 2011, doi: 10.1038/nrg3074.
[8] D. K. Soni and R. Biswas, “Role of Non-Coding RNAs in Post-Transcriptional Regulation of Lung Diseases,” Frontiers in Genetics, vol. 12, p. 2254, Nov. 2021, doi: 10.3389/FGENE.2021.767348/BIBTEX.
[9] J. Beermann, M. T. Piccoli, J. Viereck, and T. Thum, “Non-coding rnas in development and disease: Background, mechanisms, and therapeutic approaches,” Physiological Reviews, vol. 96, no. 4, pp. 1297–1325, Oct. 2016, doi: 10.1152/PHYSREV.00041.2015/ASSET/IMAGES/LARGE/Z9J0041627740006.JPEG.
[10] W. R. Jeck and N. E. Sharpless, “Detecting and characterizing circular RNAs,” Nature biotechnology, vol. 32, no. 5, pp. 453–461, 2014, doi: 10.1038/NBT.2890.
[11] F. Ozsolak et al., “Chromatin structure analyses identify miRNA promoters,” Genes & development, vol. 22, no. 22, pp. 3172–3183, Nov. 2008, doi: 10.1101/GAD.1706508.
[12] T. Derrien et al., “The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression,” Genome research, vol. 22, no. 9, pp. 1775–1789, Sep. 2012, doi: 10.1101/GR.132159.111.
[13] Y. T. F. Sasaki, T. Ideue, M. Sano, T. Mituyama, and T. Hirose, “MENepsilon/beta noncoding RNAs are essential for structural integrity of nuclear paraspeckles,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 8, pp. 2525–2530, Feb. 2009, doi: 10.1073/PNAS.0807899106.
[14] Y. Zhang et al., “Circular intronic long noncoding RNAs,” Molecular cell, vol. 51, no. 6, pp. 792–806, Sep. 2013, doi: 10.1016/J.MOLCEL.2013.08.017.
[15] W. R. Jeck et al., “Circular RNAs are abundant, conserved, and associated with ALU repeats,” RNA (New York, N.Y.), vol. 19, no. 2, pp. 141–157, Feb. 2013, doi: 10.1261/RNA.035667.112.
[16] J. Salzman, C. Gawad, P. L. Wang, N. Lacayo, and P. O. Brown, “Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types,” PloS one, vol. 7, no. 2, Feb. 2012, doi: 10.1371/JOURNAL.PONE.0030733.
[17] X. Liu, H. Liu, X. Jia, R. He, X. Zhang, and W. Zhang, “Changing Expression Profiles of Messenger RNA, MicroRNA, Long Non-coding RNA, and Circular RNA Reveal the Key Regulators and Interaction Networks of Competing Endogenous RNA in Pulmonary Fibrosis,” Frontiers in Genetics, vol. 11, p. 1098, Sep. 2020, doi: 10.3389/FGENE.2020.558095/BIBTEX.
[18] C. L. Lino Cardenas et al., “miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1,” PLoS genetics, vol. 9, no. 2, Feb. 2013, doi: 10.1371/JOURNAL.PGEN.1003291.
[19] P. Wei et al., “Transforming growth factor (TGF)-β1-induced miR-133a inhibits myofibroblast differentiation and pulmonary fibrosis,” Cell death & disease, vol. 10, no. 9, Sep. 2019, doi: 10.1038/S41419-019-1873-X.
[20] K. v. Pandit et al., “Inhibition and role of let-7d in idiopathic pulmonary fibrosis,” American journal of respiratory and critical care medicine, vol. 182, no. 2, pp. 220–229, Jul. 2010, doi: 10.1164/RCCM.200911-1698OC.
[21] H. Liu et al., “A novel lnc-PCF promotes the proliferation of TGF-β1-activated epithelial cells by targeting miR-344a-5p to regulate map3k11 in pulmonary fibrosis,” Cell death & disease, vol. 8, no. 10, p. e3137, Oct. 2017, doi: 10.1038/CDDIS.2017.500.
[22] Y. Mo, Y. Zhang, R. Wan, M. Jiang, Y. Xu, and Q. Zhang, “miR-21 mediates nickel nanoparticle-induced pulmonary injury and fibrosis,” Nanotoxicology, vol. 14, no. 9, pp. 1175–1197, Oct. 2020, doi: 10.1080/17435390.2020.1808727.
[23] N. Kuse et al., “Exosome-derived microRNA-22 ameliorates pulmonary fibrosis by regulating fibroblast-to-myofibroblast differentiation in vitro and in vivo,” Journal of Nippon Medical School, vol. 87, no. 3, pp. 118–128, 2020, doi: 10.1272/JNMS.JNMS.2020_87-302.
[24] S. Su et al., “miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program,” Nature communications, vol. 6, Oct. 2015, doi: 10.1038/NCOMMS9523.
[25] H. Liang et al., “Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during idiopathic pulmonary fibrosis,” Cell death & disease, vol. 5, no. 5, 2014, doi: 10.1038/CDDIS.2014.207.
[26] S. Das et al., “MicroRNA-326 regulates profibrotic functions of transforming growth factor-β in pulmonary fibrosis,” American Journal of Respiratory Cell and Molecular Biology, vol. 50, no. 5, pp. 882–892, May 2014, doi: 10.1165/RCMB.2013-0195OC/SUPPL_FILE/DISCLOSURES.PDF.
[27] X. Ji et al., “The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in Pulmonary Fibrosis,” Scientific reports, vol. 5, Sep. 2015, doi: 10.1038/SREP14131.
[28] G. Shepelkova et al., “MicroRNAs in serum of Interstitial lung diseases patients,” European Respiratory Journal, vol. 56, no. suppl 64, p. 1082, Sep. 2020, doi: 10.1183/13993003.CONGRESS-2020.1082.
[29] D. K. Rai, P. Sharma, and R. Kumar, “Post covid 19 pulmonary fibrosis. Is it real threat?,” The Indian Journal of Tuberculosis, vol. 68, no. 3, p. 330, Jul. 2021, doi: 10.1016/J.IJTB.2020.11.003.
[30] R. Sardar, D. Satish, and D. Gupta, “Identification of Novel SARS-CoV-2 Drug Targets by Host MicroRNAs and Transcription Factors Co-regulatory Interaction Network Analysis,” Frontiers in genetics, vol. 11, Oct. 2020, doi: 10.3389/FGENE.2020.571274.
[31] B. He, W. Zhou, Y. Rui, L. Liu, B. Chen, and X. Su, “MicroRNA-574-5p Attenuates Acute Respiratory Distress Syndrome by Targeting HMGB1,” American journal of respiratory cell and molecular biology, vol. 64, no. 2, pp. 196–207, 2021, doi: 10.1165/RCMB.2020-0112OC.
[32] N. E. Cabrera-Benitez et al., “Mechanical Ventilation–associated Lung Fibrosis in Acute Respiratory Distress Syndrome A Significant Contributor to Poor Outcome,” Anesthesiology, vol. 121, no. 1, p. 189, 2014, doi: 10.1097/ALN.0000000000000264.
[33] N. Omote and M. Sauler, “Non-coding RNAs as Regulators of Cellular Senescence in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease,” Frontiers in Medicine, vol. 7, p. 908, Dec. 2020, doi: 10.3389/FMED.2020.603047/BIBTEX.
[34] C. L. Lino Cardenas et al., “miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1,” PLoS genetics, vol. 9, no. 2, Feb. 2013, doi: 10.1371/JOURNAL.PGEN.1003291.
[35] H. Liang et al., “The Antifibrotic Effects and Mechanisms of MicroRNA-26a Action in Idiopathic Pulmonary Fibrosis,” Molecular Therapy, vol. 22, no. 6, pp. 1122–1133, Jun. 2014, doi: 10.1038/MT.2014.42.
[36] M. Fierro-Fernández et al., “miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2,” EMBO reports, vol. 16, no. 10, pp. 1358–1377, Oct. 2015, doi: 10.15252/EMBR.201540750.
[37] S. Su et al., “miR-142-5p and miR-130a-3p are regulated by IL-4 and IL-13 and control profibrogenic macrophage program,” Nature Communications 2015 6:1, vol. 6, no. 1, pp. 1–19, Oct. 2015, doi: 10.1038/ncomms9523.
[38] G. Liu et al., “miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis,” The Journal of experimental medicine, vol. 207, no. 8, pp. 1589–1597, Aug. 2010, doi: 10.1084/JEM.20100035.
[39] G. S. Lei, H. L. Kline, C. H. Lee, D. S. Wilkes, and C. Zhang, “Regulation of Collagen V Expression and Epithelial-Mesenchymal Transition by miR-185 and miR-186 during Idiopathic Pulmonary Fibrosis,” The American Journal of Pathology, vol. 186, no. 9, p. 2310, Sep. 2016, doi: 10.1016/J.AJPATH.2016.04.015.
[40] N. Balmeh, S. Mahmoudi, N. Mohammadi, and A. Karabedianhajiabadi, “Predicted therapeutic targets for COVID-19 disease by inhibiting SARS-CoV-2 and its related receptors,” Informatics in Medicine Unlocked, vol. 20, p. 100407, Jan. 2020, doi: 10.1016/J.IMU.2020.100407.
[41] S. Matsushima and J. Ishiyama, “MicroRNA-29c regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts,” American journal of physiology. Lung cellular and molecular physiology, vol. 311, no. 6, pp. L1050–L1061, 2016, doi: 10.1152/AJPLUNG.00252.2016.
[42] H. Cui et al., “MIR-34a inhibits lung fibrosis by inducing lung fibroblast senescence,” American Journal of Respiratory Cell and Molecular Biology, vol. 56, no. 2, pp. 168–178, Feb. 2017, doi: 10.1165/RCMB.2016-0163OC/SUPPL_FILE/DISCLOSURES.PDF.
[43] Y. Chen et al., “Inhibition of miR-155-5p Exerts Anti-Fibrotic Effects in Silicotic Mice by Regulating Meprin α,” Molecular Therapy - Nucleic Acids, vol. 19, pp. 350–360, Mar. 2020, doi: 10.1016/J.OMTN.2019.11.018/ATTACHMENT/DB500479-7473-4352-B8F3-69F3BF3B0AC0/MMC1.PDF.
[44] M. Kurowska-Stolarska et al., “The role of microRNA-155/liver X receptor pathway in experimental and idiopathic pulmonary fibrosis,” The Journal of Allergy and Clinical Immunology, vol. 139, no. 6, p. 1946, Jun. 2017, doi: 10.1016/J.JACI.2016.09.021.
[45] H. Tang et al., “SHIP-1, a target of miR-155, regulates endothelial cell responses in lung fibrosis,” The FASEB Journal, vol. 34, no. 2, pp. 2011–2023, Feb. 2020, doi: 10.1096/FJ.201902063R.
[46] C. L. Lino Cardenas et al., “miR-199a-5p Is upregulated during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting caveolin-1,” PLoS genetics, vol. 9, no. 2, Feb. 2013, doi: 10.1371/JOURNAL.PGEN.1003291.
[47] G. A. Rubio et al., “Mesenchymal stromal cells prevent bleomycin-induced lung and skin fibrosis in aged mice and restore wound healing,” Journal of cellular physiology, vol. 233, no. 8, pp. 5503–5512, Aug. 2018, doi: 10.1002/JCP.26418.
[48] M. Y. Yao, W. H. Zhang, W. T. Ma, Q. H. Liu, L. H. Xing, and G. F. Zhao, “microRNA-328 in exosomes derived from M2 macrophages exerts a promotive effect on the progression of pulmonary fibrosis via FAM13A in a rat model,” Experimental & Molecular Medicine 2019 51:6, vol. 51, no. 6, pp. 1–16, Jun. 2019, doi: 10.1038/s12276-019-0255-x.
[49] L. Sun et al., “Exosomal miRNA Let-7 from Menstrual Blood-Derived Endometrial Stem Cells Alleviates Pulmonary Fibrosis through Regulating Mitochondrial DNA Damage,” Oxidative Medicine and Cellular Longevity, vol. 2019, 2019, doi: 10.1155/2019/4506303.
[50] M. W. Liu, M. X. Su, D. Y. Tang, L. Hao, X. H. Xun, and Y. Q. Huang, “Ligustrazin increases lung cell autophagy and ameliorates paraquat-induced pulmonary fibrosis by inhibiting PI3K/Akt/mTOR and hedgehog signalling via increasing miR-193a expression,” BMC Pulmonary Medicine, vol. 19, no. 1, pp. 1–16, Feb. 2019, doi: 10.1186/S12890-019-0799-5/FIGURES/12.
[51] B. Liu et al., “MicroRNA-708-3p as a potential therapeutic target via the ADAM17-GATA/STAT3 axis in idiopathic pulmonary fibrosis,” Experimental & Molecular Medicine 2018 50:3, vol. 50, no. 3, pp. e465–e465, Mar. 2018, doi: 10.1038/emm.2017.311.
[52] C. Li et al., “Crosstalk of mRNA, miRNA, lncRNA, and circRNA and Their Regulatory Pattern in Pulmonary Fibrosis,” Molecular Therapy - Nucleic Acids, vol. 18, pp. 204–218, Dec. 2019, doi: 10.1016/J.OMTN.2019.08.018.
[53] R. Li et al., “Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis,” International Journal of Molecular Medicine, vol. 42, no. 6, p. 3256, Dec. 2018, doi: 10.3892/IJMM.2018.3892.
[54] B. Zhou and J. W. Yu, “A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-β1,” Biochemical and biophysical research communications, vol. 487, no. 4, pp. 769–775, Jun. 2017, doi: 10.1016/J.BBRC.2017.04.044.
[55] J. Li, P. Li, G. Zhang, P. Qin, D. Zhang, and W. Zhao, “CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting proliferation and activation of fibroblasts,” Cell Death & Disease 2020 11:7, vol. 11, no. 7, pp. 1–15, Jul. 2020, doi: 10.1038/s41419-020-02747-9.
[56] Y. Zhang et al., “Roles of microRNA-146a and microRNA-181b in regulating the secretion of tumor necrosis factor-α and interleukin-1β in silicon dioxide-induced NR8383 rat macrophages,” Molecular Medicine Reports, vol. 12, no. 4, pp. 5587–5593, Oct. 2015, doi: 10.3892/MMR.2015.4083/HTML.
[57] X. Yang et al., “Silica-induced initiation of circular ZC3H4RNA/ZC3H4 pathway promotes the pulmonary macrophage activation,” The FASEB Journal, vol. 32, no. 6, pp. 3264–3277, Jun. 2018, doi: 10.1096/FJ.201701118R.
[58] Z. Zhou et al., “circRNA mediates silica-induced macrophage activation via HECTD1/ZC3H12A-dependent ubiquitination,” Theranostics, vol. 8, no. 2, pp. 575–592, 2018, doi: 10.7150/THNO.21648.
[59] S. Fang et al., “circHECTD1 promotes the silica-induced pulmonary endothelial–mesenchymal transition via HECTD1,” Cell Death & Disease 2018 9:3, vol. 9, no. 3, pp. 1–16, Mar. 2018, doi: 10.1038/s41419-018-0432-1.
[60] Z. Cao et al., “circHIPK2-mediated σ-1R promotes endoplasmic reticulum stress in human pulmonary fibroblasts exposed to silica,” Cell Death & Disease 2017 8:12, vol. 8, no. 12, pp. 1–13, Dec. 2017, doi: 10.1038/s41419-017-0017-4.
[61] Y. Cheng et al., “CircRNA-012091/PPP1R13B-mediated lung fibrotic response in silicosis via endoplasmic reticulum stress and autophagy,” American Journal of Respiratory Cell and Molecular Biology, vol. 61, no. 3, pp. 380–391, Aug. 2019, doi: 10.1165/RCMB.2019-0017OC/SUPPL_FILE/DISCLOSURES.PDF.
[62] B. Son et al., “CYP2E1 regulates the development of radiation-induced pulmonary fibrosis via ER stress-and ROS-dependent mechanisms,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 313, no. 5, pp. L916–L929, Nov. 2017, doi: 10.1152/AJPLUNG.00144.2017/ASSET/IMAGES/LARGE/ZH50101773140009.JPEG.
[63] H. Li et al., “FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary brosis Characteristic Medical Center of the Chinese People’s Armed Police Force Xiaoping Li Tianjin First Central Hospital”, doi: 10.21203/rs.3.rs-900230/v1.
[64] W. Yao et al., “The CDR1as/miR-7/TGFBR2 Axis Modulates EMT in Silica-Induced Pulmonary Fibrosis,” Toxicological sciences : an official journal of the Society of Toxicology, vol. 166, no. 2, pp. 465–478, Dec. 2018, doi: 10.1093/TOXSCI/KFY221.
[65] Q. Xu et al., “The role of macrophage–fibroblast interaction in lipopolysaccharide-induced pulmonary fibrosis: an acceleration in lung fibroblast aerobic glycolysis,” Laboratory Investigation 2021, pp. 1–8, Nov. 2021, doi: 10.1038/s41374-021-00701-7.
[66] Z. Ye et al., “The differential expression of novel circular RNAs in an acute lung injury rat model caused by smoke inhalation,” Journal of physiology and biochemistry, vol. 74, no. 1, pp. 25–33, Feb. 2018, doi: 10.1007/S13105-017-0598-5.
[67] Y. Jia et al., “Circular RNA 406961 interacts with ILF2 to regulate PM2.5-induced inflammatory responses in human bronchial epithelial cells via activation of STAT3/JNK pathways,” Environment International, vol. 141, p. 105755, Aug. 2020, doi: 10.1016/J.ENVINT.2020.105755.
[68] J. J. Gokey et al., “MEG3 is increased in idiopathic pulmonary fibrosis and regulates epithelial cell differentiation,” JCI Insight, vol. 3, no. 17, Sep. 2018, doi: 10.1172/JCI.INSIGHT.122490.
[69] H. Cui et al., “Long noncoding RNA Malat1 regulates differential activation of macrophages and response to lung injury,” JCI Insight, vol. 4, no. 4, Feb. 2019, doi: 10.1172/JCI.INSIGHT.124522.
[70] K. Fukushima et al., “Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis,” Immunity, vol. 52, no. 3, pp. 542-556.e13, Mar. 2020, doi: 10.1016/J.IMMUNI.2020.02.007.
[71] X. Song et al., “lncITPF Promotes Pulmonary Fibrosis by Targeting hnRNP-L Depending on Its Host Gene ITGBL1,” Molecular Therapy, vol. 27, no. 2, p. 380, Feb. 2019, doi: 10.1016/J.YMTHE.2018.08.026.
[72] Y. Gao et al., “Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis,” BMC Pulmonary Medicine, vol. 17, no. 1, p. 1, Dec. 2017, doi: 10.1186/S12890-017-0516-1/FIGURES/7.
[73] W. Qian, X. Cai, and Q. Qian, “Sirt1 antisense long non-coding RNA attenuates pulmonary fibrosis through sirt1-mediated epithelial-mesenchymal transition,” Aging, vol. 12, no. 5, pp. 4322–4336, Mar. 2020, doi: 10.18632/AGING.102882.
[74] W. Qian et al., “lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial–mesenchymal transition by competitively binding miR-141-3p,” Cell Death & Disease 2019 10:2, vol. 10, no. 2, pp. 1–12, Feb. 2019, doi: 10.1038/s41419-019-1339-1.
[75] M. Moazzam-Jazi, H. Lanjanian, S. Maleknia, M. Hedayati, and M. S. Daneshpour, “Interplay between SARS-CoV-2 and human long non-coding RNAs,” Journal of cellular and molecular medicine, vol. 25, no. 12, pp. 5823–5827, Jun. 2021, doi: 10.1111/JCMM.16596.
[76] C. Meydan, N. Madrer, and H. Soreq, “The Neat Dance of COVID-19: NEAT1, DANCR, and Co-Modulated Cholinergic RNAs Link to Inflammation,” Frontiers in Immunology, vol. 11, p. 2638, Oct. 2020, doi: 10.3389/FIMMU.2020.590870/BIBTEX.
[77] H. Li, H. Shi, N. Ma, P. Zi, Q. Liu, and R. Sun, “BML-111 alleviates acute lung injury through regulating the expression of lncRNA MALAT1,” Archives of Biochemistry and Biophysics, vol. 649, pp. 15–21, Jul. 2018, doi: 10.1016/J.ABB.2018.04.016.
[78] L. Wei, J. Li, Z. Han, Z. Chen, and Q. Zhang, “Silencing of lncRNA MALAT1 Prevents Inflammatory Injury after Lung Transplant Ischemia-Reperfusion by Downregulation of IL-8 via p300,” Molecular Therapy - Nucleic Acids, vol. 18, pp. 285–297, Dec. 2019, doi: 10.1016/J.OMTN.2019.05.009.
[79] R. Vishnubalaji, H. Shaath, and N. M. Alajez, “Protein Coding and Long Noncoding RNA (lncRNA) Transcriptional Landscape in SARS-CoV-2 Infected Bronchial Epithelial Cells Highlight a Role for Interferon and Inflammatory Response,” Genes 2020, Vol. 11, Page 760, vol. 11, no. 7, p. 760, Jul. 2020, doi: 10.3390/GENES11070760.
[80] M. Moazzam-Jazi, H. Lanjanian, S. Maleknia, M. Hedayati, and M. S. Daneshpour, “Interplay between SARS-CoV-2 and human long non-coding RNAs,” Journal of cellular and molecular medicine, vol. 25, no. 12, pp. 5823–5827, Jun. 2021, doi: 10.1111/JCMM.16596.
[81] Q. Lu et al., “The lncRNA H19 Mediates Pulmonary Fibrosis by Regulating the miR-196a/COL1A1 Axis,” Inflammation, vol. 41, no. 3, pp. 896–903, Jun. 2018, doi: 10.1007/S10753-018-0744-4/FIGURES/3.
[82] A. Zaki, M. S. Ali, V. Hadda, S. M. Ali, A. Chopra, and T. Fatma, “Long non-coding RNA (lncRNA): A potential therapeutic target in acute lung injury,” Genes & Diseases, Aug. 2021, doi: 10.1016/J.GENDIS.2021.07.004.
[83] M. Selman and A. Pardo, “Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model,” American journal of respiratory and critical care medicine, vol. 189, no. 10, pp. 1161–1172, May 2014, doi: 10.1164/RCCM.201312-2221PP.
[84] F. J. Martinez et al., “Idiopathic pulmonary fibrosis,” Nature reviews. Disease primers, vol. 3, Oct. 2017, doi: 10.1038/NRDP.2017.74.
[85] J. J. Gokey et al., “MEG3 is increased in idiopathic pulmonary fibrosis and regulates epithelial cell differentiation,” JCI insight, vol. 3, no. 17, Sep. 2018, doi: 10.1172/JCI.INSIGHT.122490.
[86] K. Fukushima et al., “Dysregulated Expression of the Nuclear Exosome Targeting Complex Component Rbm7 in Nonhematopoietic Cells Licenses the Development of Fibrosis,” Immunity, vol. 52, no. 3, pp. 542-556.e13, Mar. 2020, doi: 10.1016/J.IMMUNI.2020.02.007.
[87] Y. Gao et al., “Regulation of TERRA on telomeric and mitochondrial functions in IPF pathogenesis,” BMC Pulmonary Medicine, vol. 17, no. 1, p. 1, Dec. 2017, doi: 10.1186/S12890-017-0516-1.
[88] X. Hao, Y. Du, L. Qian, D. Li, and X. Liu, “Upregulation of long noncoding RNA AP003419.16 predicts high risk of aging‑associated idiopathic pulmonary fibrosis,” Molecular medicine reports, vol. 16, no. 6, pp. 8085–8091, Dec. 2017, doi: 10.3892/MMR.2017.7607.
[89] X. Hao, Y. Du, L. Qian, D. Li, and X. Liu, “Upregulation of long noncoding RNA AP003419.16 predicts high risk of aging‑associated idiopathic pulmonary fibrosis,” Molecular medicine reports, vol. 16, no. 6, pp. 8085–8091, Dec. 2017, doi: 10.3892/MMR.2017.7607.
[90] X. Song et al., “lncITPF Promotes Pulmonary Fibrosis by Targeting hnRNP-L Depending on Its Host Gene ITGBL1,” Molecular therapy : the journal of the American Society of Gene Therapy, vol. 27, no. 2, pp. 380–393, Feb. 2019, doi: 10.1016/J.YMTHE.2018.08.026.
[91] C. Li et al., “Crosstalk of mRNA, miRNA, lncRNA, and circRNA and Their Regulatory Pattern in Pulmonary Fibrosis,” Molecular therapy. Nucleic acids, vol. 18, pp. 204–218, Dec. 2019, doi: 10.1016/J.OMTN.2019.08.018.
[92] H. Cui et al., “Long noncoding RNA Malat1 regulates differential activation of macrophages and response to lung injury,” JCI insight, vol. 4, no. 4, Feb. 2019, doi: 10.1172/JCI.INSIGHT.124522.
[93] L. Sai et al., “Profiling long non-coding RNA changes in silica-induced pulmonary fibrosis in rat,” Toxicology letters, vol. 310, pp. 7–13, Aug. 2019, doi: 10.1016/J.TOXLET.2019.04.003.
[94] K. Ma et al., “LncRNA Gm16410 regulates PM 2.5-induced lung Endothelial-Mesenchymal Transition via the TGF-β1/Smad3/p-Smad3 pathway,” Ecotoxicology and environmental safety, vol. 205, Dec. 2020, doi: 10.1016/J.ECOENV.2020.111327.
[95] S. H. Ahn, D. Gu, Y. Koh, H. S. Lee, and S. W. Chi, “AGO CLIP-based imputation of potent siRNA sequences targeting SARS-CoV-2 with antifibrotic miRNA-like activity,” Scientific Reports 2021 11:1, vol. 11, no. 1, pp. 1–15, Sep. 2021, doi: 10.1038/s41598-021-98708-z.